FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burd	len
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		n [*]														•	, ,	Issuer Owner
(Last) (First) (Middle) C/O THIRD SECURITY, LLC				3. Date of Earliest Transaction (Month/Day/Year) 12/11/2017									Officer (g below)	jive titl	e		(specify v)	
				[1. If <i>A</i>	Amendmen	ıt, Dat	e of Origir	nal F	led (Month	h/Day	//Year)	6. Inc Line)					
VA		2414	1										X		•		-	
(Sta	te)	(Zip)																
	Tak	ole I -	· Non-D	erivat	ive	Securiti	es A	cquired	, Di	sposed	of,	or Ber	neficially	Owned				
urity (Instr	. 3)		Date		E:) E:	ecution D							. 3, 4 and	Securities Beneficially Owned		Form: (D) or Indired	Direct	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount		(A) or (D)	Price	Reported Transaction		(Instr.	4)	(Instr. 4)
ock			12/11	/2017				P		2,567,1	121	A	\$0.77	5,773,62	6(1)	:	I .	by NRM VII Holdings ⁽²⁾
ock			12/11	/2017				P		155,34	47	A	\$0.77	349,386	5(1)	:		by Kapital Joe ⁽²⁾
ock			12/11	/2017				P		4,80	5	A	\$0.77	10,806	(1)		I :	by Mascara Kaboom ⁽²⁾
ock														2,133,59	5 ⁽¹⁾	:		by Intrexon ⁽³⁾
		Та												ied				
Derivative Conversion Date Execut Security (Instr. 3) or Exercise (Month/Day/Year) any		tion Date, if Transaction Code (Inst					6. Date Exercisable and Expiration Date (Month/Day/Year)			Securities Underlyin		erlying	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficial Owned Following	tive ties icially d ving	Form: Direct (D) or Indirect	Beneficial Ownership ct (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable			Title		Amount or Number of Shares		Transa	action(s)		
\$0.77	12/11/2017			P		2,567,121		12/11/20	17 1	2/11/2022			2,567,12	1 (4)	2,56	57,121	I	by NRM VII Holdings ⁽²⁾
\$0.77	12/11/2017			P		155,347		12/11/20	17 1	2/11/2022			155,347	(4)	155	5,347	I	by Kapital Joe ⁽²⁾
\$0.77	12/11/2017			P		4,805		12/11/20	17 1	2/11/2022			4,805	(4)	4,	805	I	by Mascara Kaboom ⁽²⁾
	(Firs SECURI / E AVEN / VA (Sta urity (Instruction of Exercise Price of Derivative Security \$0.77	(First) SECURITY, LLC VA (State) Tak urity (Instr. 3) Ock Ock Ock Ock Ock Ock Ock Ock Ock Oc	(First) (Middl SECURITY, LLC VE AVENUE VA 2414 (State) (Zip) Table I - urity (Instr. 3) Ock Ock Conversion or Exercise Price of Derivative Security \$0.77 12/11/2017 \$0.77 12/11/2017	(First) (Middle) SECURITY, LLC YE AVENUE Table I - Non-D urity (Instr. 3) 2. Transa Date (Month/L ock 12/11 ock Table II - D (ce 2. Table II - D (ce 12/11 ock 12/11/2017	NDAL J SECURITY, LLC	SECURITY, LLC SECURITY SECURIT	Conversion of Exercisor Price of Exercisor Price of Exercisor Price of Exercisor Price of Exercisor Security Security	Fibrocell Scie	SECURITY, LLC	SECURITY, LLC	Fibrocell Science, Inc. FCSC 3. Date of Earliest Transaction (Month/Day/Yei 12/11/2017 4. If Amendment, Date of Original Filed (Month/Day/Year) 12/11/2017 4. If Amendment, Date of Original Filed (Month/Day/Year) 12/11/2017 4. If Amendment, Date of Original Filed (Month/Day/Year) 12/11/2017 4. If Amendment, Date of Original Filed (Month/Day/Year) 12/11/2017 24. Deemed Execution Date, if any (Month/Day/Year) 12/11/2017 24. Deemed Execution Date, if any (Month/Day/Year) 12/11/2017 25. Securities Acquired, Disposed of, (e.g., puts, calls, warrants, options, convertile Conversion 12/11/2017 25. Number of Darivative Date (e.g., puts, calls, warrants, options, convertile Securities 12/11/2017	Fibrocell Science, Inc. FCSC	Fibrocell Science, Inc. [FCSC]	Fibrocell Science, Inc. FCSC	Check all application Check all applications Community Code Check all applications Check all applications Code Check all applications Code Check all applications Check all applications Code Check all applications Check all applications Code Check all applications Check all applications Check all applications Code Check all applications Code Check all applications Check all applications Code Check all applications Code Check all applications Check all applications Check all applications Code Check all applications Check all app	SECURITY, LLC	Check all applicables Check all all all all all all all all all al	Fibrocell Science, Inc. FCSC

(Last)	(First)	(Middle)	
C/O THIRD SEC	CURITY, LLC		
1881 GROVE A	VENUE		
(Street)			
RADFORD	VA	24141	
(City)	(State)	(Zip)	
i. Name and Addre	ss of Reporting Per	5011	
INTREXON (Last)		(Middle)	
(Last) C/O LEGAL DE	(First)	(Middle)	
(Last) C/O LEGAL DE	(First)	, ,	
(Last) C/O LEGAL DE 20374 SENECA	(First) PARTMENT	, ,	
(Last) C/O LEGAL DE 20374 SENECA (Street)	(First) PARTMENT . MEADOWS PA	RKWAY	
(Last) C/O LEGAL DE 20374 SENECA	(First) PARTMENT . MEADOWS PA	, ,	

Explanation of Responses:

- 1. The indicated number of common shares is reflective of a 1-for-3 reverse stock split effected by the issuer on March 13, 2017.
- 2. Randal J. Kirk controls Kapital Joe, LLC ("Kapital Joe"), Mascara Kaboom, LLC ("Mascara Kaboom") and NRM VII Holdings I, LLC ("NRM VII Holdings"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- 3. Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon Corporation ("Intrexon") and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- 4. The indicated number of warrants to purchase common stock of the issuer were received in connection with the purchase of common stock in an underwritten public offering of the issuer, which closed on December 11, 2017 (the "Offering"). In the Offering, each share of common stock was sold together with a common warrant to purchase one share of common stock at a combined effective price of \$0.77 per share and accompanying common warrant.

 /s/ Randal J. Kirk, CEO of
 12/13/2017

 Intrexon Corporation
 12/13/2017

 /s/ Randal J. Kirk
 12/13/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.